NEUROShield

by In-Med Prognostics L3C  · Based in India → — AI-Powered Precision Neuroimaging
Neurology Neurosurgery Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

NEUROShield by In-Med Prognostics L3C is an FDA 510(k) cleared, fully automated brain geometry-based quantifying analytics tool and cloud platform. It leverages AI, Deep Net, and 3D Convolutional Networks to provide clinical decision support for neurologists, neuroradiologists, and neurosurgeons. The platform processes 3D MR images to automatically calculate brain volumes and offers comprehensive brain structure analysis, including ethnicity-specific reference ranges adjusted to age and gender.

NEUROShield assists physicians in devising optimal treatment plans for patients with neurodegenerative diseases such as Dementia, Alzheimer’s Disease, Parkinson’s, and Epilepsy, by enabling early detection of atrophy. Additionally, the NeuroShield CT TBI product provides AI-based neurotrauma screening and quantification, automating the detection and quantification of intracranial hemorrhage, fracture, and midline shift, which is crucial for rapid clinical decision-making in critical care. The tool aims to reduce the burden on radiologists by automating MRI imaging analysis and providing accurate, actionable results.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated brain geometry-based quantifying analytics
  • Utilizes AI/Deep Net/3D Convolutional Networks
  • Processes 3D MR images for brain volumetry
  • Calculates brain volumes and provides comprehensive brain structure analysis
  • Assists in treatment planning for neurodegenerative diseases
  • Offers ethnicity-specific reference ranges adjusted to age and gender
  • Supports early detection of atrophy in neurodegenerative disorders
  • Automates MRI imaging analysis to reduce radiologist workload
  • Cloud-based platform with centralized scan management
  • NeuroShield CT for AI-based neurotrauma screening and quantification (bleed, fracture, midline shift detection)

Use Cases

  • Clinical decision support for neurologists, neuroradiologists, and neurosurgeons
  • Diagnosis and management of neurodegenerative diseases (Dementia, Alzheimer's, Parkinson's, Epilepsy)
  • Early intervention and monitoring for neurodegenerative disorders
  • Neurotrauma screening, quantification, and triage management (TBI, intracranial hemorrhage, fracture, midline shift)
  • Automating image processing to improve efficiency in radiology workflows
  • Research support for clinical imaging-based projects and building databanks

What Physicians Need to Know

Evidence Base
NEUROShield is an AI/Deep Net/3D Convolutional Networks based cloud platform that utilizes pattern recognition and deep learning to develop clinical biomarkers for early prognosis and differential diagnosis of neurodegenerative diseases. Peer-reviewed research supports that volumetry and atrophic changes can be detected as early as 42 years in females and 50 years in males. It is the first tool to provide reference ranges adjustable to age, gender, and ethnicity. The core algorithm is locked, with modifications requiring FDA review.
Clinical Validation Studies
The tool has received US FDA 510(k) clearance. A trial involving 280 subjects from various US regions demonstrated high accuracy across different scanner magnetic strengths, clinical subgroups, gender, age, and slice thickness. Segmentation analysis showed remarkable accuracy, reliability, and effectiveness, with an average Dice coefficient of 0.91 and Hausdorff distance of 3.8 mm. Subgroup error analysis confirmed high accuracy (Dice score >90%, Hausdorff distance <4 mm) across diverse parameters. The algorithm was trained using a dataset of 186 cases from multiple sites in India.
Alert Fatigue Management
While the primary NEUROShield MR Volumetry tool focuses on providing quantitative analysis rather than generating frequent alerts, its aim is to reduce radiologist burden by automating MRI analysis and providing actionable insights. A related product, NeuroShield CT TBI, is designed to promptly alert neurologists to critical pathologies and efficiently prioritize cases, indicating an inherent focus on meaningful alerts.
Differential Diagnosis Support
NEUROShield provides actionable, quantitative, objective decision-making support for neuro-physicians for differential diagnosis. It aids in assessing conditions such as Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease, Parkinson's, Multiple Sclerosis (MS), epilepsy, and tuberculosis (TB) more efficiently through volumetric analysis of 3D MRI images.
Clinical Workflow Integration
NEUROShield is a cloud-based platform also available as a desktop application. It is currently in clinical use in over 220+ sites worldwide. The NeuroShield CT TBI product is designed for seamless integration into clinical and radiology workflows to prioritize critical cases. InMed.AI also offers NeuroFlou2122, a neurology workflow software that streamlines operations from scan intake to report delivery, reducing radiologist workload.
Physician Tip

Leverage NEUROShield's automated brain volumetric analysis to enhance diagnostic accuracy and reduce manual workload in neurodegenerative disease assessment. Utilize the ethnicity, age, and gender-specific reference ranges for more personalized and precise patient evaluations. Integrate the quantitative data provided by NEUROShield into your treatment planning for conditions like Dementia, Alzheimer's, Parkinson's, and Epilepsy to support early intervention and monitor disease progression. For neurotrauma cases, consider the NeuroShield CT TBI tool for rapid identification and prioritization of critical pathologies.

NEUROShield operates as a cloud-based platform with a complementary desktop application, offering flexibility in deployment. It is part of InMed.AI's comprehensive suite of neuroimaging intelligence tools, which includes NeuroShield CT TBI for neurotrauma screening and NeuroFlo for overall neurology workflow optimization. This ecosystem suggests a design focused on streamlining clinical and radiology operations, from image acquisition to report generation and delivery.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-based platform; integrates with Modality, PACS, HMIS, RIS, and on-site/on-premise solutions.
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status 1 AI-estimated

NEUROShield received US FDA 510(k) clearance (K220034) on September 14, 2023, as a medical image management and processing system (Regulation Number: 21 CFR 892.2050, Product Code: QIH).
Integrations
EHR Not specified
Specialties Neurology, Neurosurgery, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate NEUROShield

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Imaging Technology News
InMed AI Receives FDA 510(k) clearance for NeuroShield | Imaging Technology News
InMed.AI received FDA 510(k) clearance for NeuroShield, an AI-powered tool that automatically quantifies brain volumes from 3D MR images to assist in treatment plans for neurodegenerative diseases. NeuroShield is currently in clinical use in over 220 sites worldwide and is the first to provide ethnicity-specific reference ranges.
2023-11
Applied Radiology
New AI-Powered Tool Automatically Quantifies Brain Volumes Using MR Data
InMed.AI's NeuroShield, an AI-driven platform, has received US FDA 510(k) clearance for its ability to automatically quantify brain volumes from MR images, aiding in the diagnosis and treatment of neurodegenerative diseases. The tool is in use at over 220 sites globally and offers ethnicity-specific reference ranges.
2023-11
AuntMinnie
InMed.AI gets FDA nod for NeuroShield - AuntMinnie
InMed.AI has received 510(k) clearance from the U.S. FDA for its NeuroShield MRI technology, a fully automated brain geometry- and cloud-based platform for neurologists and neuroradiologists. It takes 3D MR images to calculate brain volumes for neurodegenerative diseases and has shown high accuracy in trials.
2023-11
Medical Device Network
InMed AI secures FDA 510(k) clearance for NeuroShield - Medical Device Network
InMed AI has secured US FDA 510(k) clearance for NeuroShield, an AI-powered tool that quantifies brain volumes from 3D MR images to support the diagnosis and treatment of neurodegenerative diseases. The device is noted as the first to offer ethnicity-specific reference ranges.
2023-11
PR Newswire
InMed AI Receives First-of-Its-Kind FDA 510(k) Clearance for NeuroShieldu2122
InMed.AI announced FDA 510(k) clearance for NeuroShieldu2122, an AI-driven tool and cloud platform that uses 3D Convolutional Networks for brain geometry-based quantifying analytics. It assists physicians in treatment plans for neurodegenerative conditions and is operational in over 220 sites globally.
2023-11
NeurologyLive
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
NeuroShield, an AI-powered brain volume quantification tool from InMed.AI, has received 510(k) clearance from the FDA. It provides automated brain volume calculations from MRI images, aiding in the early detection and treatment of neurodegenerative conditions.
2023-11
BioSpectrum India
InMed AI receives US FDA 510(k) clearance for NeuroShield that quantifies brain volumes
Pune-based InMed Prognostics Inc. received US FDA 510(k) clearance for NeuroShieldu2122, an AI-powered platform that quantifies brain volumes using MRI data. It's designed as a clinical decision support tool for neurologists and neuroradiologists, offering ethnicity-adjustable reference ranges.
2023-11
BioSpectrum India
In-Med develops NeuroShield CT, AI tool to help reduce mortality rates in neurotrauma
In-Med AI launched 'Neuroshield CT TBI', an AI-based neurotrauma screening and quantification tool to aid in identifying and quantifying pathologies related to Traumatic Brain Injury (TBI). This tool automates image processing for rapid and informed decision-making in critical care.
2024-02

Videos

Product demos, reviews, and walkthroughs for NEUROShield.

View all on YouTube

No FAQs available yet for this tool.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.